AYTU BIOPHARMA, INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
AYTU BIOPHARMA, INC (AYTU) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.38 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2021-05-17
- AYTU BIOPHARMA, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-03-31 was $1.38M.
- AYTU BIOPHARMA, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-12-31 was $508.06K, a 213.11% increase year-over-year.
- AYTU BIOPHARMA, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-09-30 was $454.92K, a 175.42% increase year-over-year.
- AYTU BIOPHARMA, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2019-12-31 was $162.26K, a 294.73% increase year-over-year.
- AYTU BIOPHARMA, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $348.51K, a 86.07% decline from fiscal 2017.
- AYTU BIOPHARMA, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2017 was $2.50M, a 177.10% increase from fiscal 2016.
- AYTU BIOPHARMA, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2016 was $902.95K, a 11.30% decline from fiscal 2015.
- AYTU BIOPHARMA, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2015 was $1.02M, a 103.71% increase from fiscal 2014.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $1.38M 10-Q · filed 2021-05-17 | $1.89M derived: sum of 2 quarters · filed 2021-05-17 | $2.34M derived: sum of 3 quarters · filed 2021-05-17 | ||
| 2020-12-31 | $508.06K 10-Q · filed 2021-05-17 | $962.98K derived: sum of 2 quarters · filed 2021-05-17 | |||
| 2020-09-30 | $454.92K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $162.26K 10-Q · filed 2021-05-17 | $327.44K derived: sum of 2 quarters · filed 2021-05-17 | |||
| 2019-09-30 | $165.17K 10-Q · filed 2021-05-17 | ||||
| 2019-03-31 | $15.31K 10-Q · filed 2019-05-14 | $56.42K derived: sum of 2 quarters · filed 2019-05-14 | $208.53K derived: sum of 3 quarters · filed 2019-11-14 | $269.04K derived: sum of 4 quarters · filed 2019-11-14 | |
| 2018-12-31 | $41.11K 10-Q · filed 2019-05-14 | $106.67K 10-Q · filed 2019-05-14 | $253.73K derived: sum of 3 quarters · filed 2019-11-14 | $266.05K derived: sum of 4 quarters · filed 2019-11-14 | |
| 2018-09-30 | $152.11K 10-Q · filed 2019-11-14 | $65.56K 10-Q · filed 2018-11-07 | $212.62K derived: sum of 2 quarters · filed 2019-11-14 | $224.94K derived: sum of 3 quarters · filed 2019-11-14 | $305.52K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $60.51K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $72.83K derived: sum of 2 quarters · filed 2019-05-14 | $153.41K derived: sum of 3 quarters · filed 2019-05-14 | $348.51K 10-K · filed 2018-09-06 | |
| 2018-03-31 | $12.32K 10-Q · filed 2019-05-14 | $92.91K derived: sum of 2 quarters · filed 2019-05-14 | $288.01K 10-Q · filed 2018-05-14 | $548.11K derived: sum of 4 quarters · filed 2019-05-14 | |
| 2017-12-31 | $80.58K 10-Q · filed 2019-05-14 | $275.69K 10-Q · filed 2018-02-08 | $535.79K derived: sum of 3 quarters · filed 2019-05-14 | $1.35M derived: sum of 4 quarters · filed 2019-05-14 | |
| 2017-09-30 | $195.10K 10-Q · filed 2019-05-14 | $455.21K derived: sum of 2 quarters · filed 2019-05-14 | $1.27M derived: sum of 3 quarters · filed 2019-05-14 | $1.65M derived: sum of 4 quarters · filed 2019-05-14 | |
| 2017-06-30 | $260.10K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $1.08M derived: sum of 2 quarters · filed 2018-09-06 | $1.46M derived: sum of 3 quarters · filed 2018-09-06 | $2.50M 10-K · filed 2018-09-06 | |
| 2017-03-31 | $816.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-11 | $1.20M derived: sum of 2 quarters · filed 2017-05-11 | $2.24M 10-Q · filed 2017-05-11 | $2.60M derived: sum of 4 quarters · filed 2017-08-31 | |
| 2016-12-31 | $381.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $1.43M 10-Q · filed 2017-02-09 | $1.78M derived: sum of 3 quarters · filed 2017-08-31 | $2.08M derived: sum of 4 quarters · filed 2017-08-31 | |
| 2016-09-30 | $1.04M 10-Q · filed 2016-11-07 | $1.40M derived: sum of 2 quarters · filed 2017-08-31 | $1.70M derived: sum of 3 quarters · filed 2017-08-31 | $1.88M derived: sum of 4 quarters · filed 2017-08-31 | |
| 2016-06-30 | $355.84K derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $652.06K derived: sum of 2 quarters · filed 2017-08-31 | $834.62K derived: sum of 3 quarters · filed 2017-08-31 | $902.95K 10-K · filed 2017-08-31 | |
| 2016-03-31 | $296.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-11 | $478.79K derived: sum of 2 quarters · filed 2016-05-11 | $547.11K 10-Q · filed 2016-05-11 | ||
| 2015-12-31 | $182.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-11 | $250.89K 10-Q · filed 2016-02-11 | |||
| 2015-09-30 | $68.32K 10-Q · filed 2015-11-06 | ||||
| 2015-06-30 | $1.02M 10-K · filed 2016-09-01 | ||||
| 2014-06-30 | $499.69K 10-K · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |